TSHA
NASDAQ HealthcareTaysha Gene Therapies, Inc. - Common Stock
Biotechnology
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
�� 市场数据
| 价格 | $6.43 |
|---|---|
| 成交量 | 6,078,049 |
| 市值 | 1.85B |
| 贝塔系数 | 1.080 |
| RSI（14日） | 84.7 超买 |
| 200日均线 | $4.16 |
| 50日均线 | $4.63 |
| 52周最高 | $6.50 |
| 52周最低 | $1.22 |
| Forward P/E | -15.78 |
| Price / Book | 7.42 |
🎯 投资策略评分
TSHA 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (84/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🔪 Falling Knife (3/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 TSHA in your text
粘贴任何文章、记录或帖子 — 工具将提取 TSHA 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.